# CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer

> **NCT07057349** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cytosite Biopharma Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Cancer
- Unresectable Solid Tumor

## Interventions

- **DRUG:** [18F]CSB-321

## Key facts

- **NCT ID:** NCT07057349
- **Lead sponsor:** Cytosite Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09
- **Final completion:** 2029-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057349, "CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07057349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*